Home / Business and Economy / AstraZeneca and Sun Pharma Expand Access to Hyperkalaemia Treatment Across India
AstraZeneca and Sun Pharma Expand Access to Hyperkalaemia Treatment Across India
17 Nov
Summary
- AstraZeneca and Sun Pharma sign second brand partnership for Sodium Zirconium Cyclosilicate
- Aim to accelerate availability of innovative treatment for Hyperkalaemia to more patients
- AstraZeneca to market therapy as Lokelma, Sun Pharma to promote it as Gimliand
In a significant development on November 17, 2025, AstraZeneca Pharma India and Sun Pharmaceutical Industries have entered into a second brand partnership to accelerate the availability of Sodium Zirconium Cyclosilicate (SZC), an innovative and highly effective treatment for Hyperkalaemia, to patients across India.
Under the agreement, both companies will jointly promote, market, and distribute the therapy, with AstraZeneca marketing it as Lokelma and Sun Pharma promoting it as Gimliand. This collaboration aims to significantly expand the reach of this vital treatment and help address the growing burden of Hyperkalaemia in the country.
Hyperkalaemia is a serious condition that disproportionately affects patients with chronic kidney disease and heart failure. The partnership between the two pharmaceutical giants is a significant step in empowering healthcare professionals and enhancing the quality of life for patients suffering from this condition in India.
